Icon Plc and Medpace are both CROs, but Icon focuses on large pharma with an aggressive M&A strategy, unlike Medpace's small biotech focus. Initially impressed by Icon's financials, we purchased ...
The Keeneland September Sale continues as the industry’s gold standard, offering over 4,000 yearlings across multiple books and two full weeks of action. Book 1 delivered the expected fireworks, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results